Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of CR011-vcMMAE in patients with locally
advanced and metastatic breast cancer. CR011-vcMMAE will be administered intravenously (IV)
once every 3 weeks (q3w) to cohorts of 3-6 patients to confirm the maximum tolerated dose
(MTD) in breast cancer patients. Once the MTD is confirmed, up to 25 patients with locally
advanced or metastatic breast cancer will be enrolled into the Phase II portion of the trial
to further evaluate the safety and efficacy of CR011-vcMMAE.